arrow
F

Frances S Mair

university of glasgow
H指数:83
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Translational framework for implementation evaluation and research: a critical approach to patient-centred equity design

实施评估和研究的转化框架: 以患者为中心的公平设计的关键方法

2025-11-050
OA
Baseline characteristics of people experiencing homelessness in the PHOENIx community pharmacy multicentre pilot randomised controlled trial

PHOENIx社区药房多中心试点随机对照试验中经历无家可归人群的基线特征

2025-10-250
OAAI
A pilot randomised controlled trial of the Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP)

一项关于由药剂师和顾问呼吸内科医师提供的针对患有中至重度慢性阻塞性肺疾病及合并症的 Tailored Intervention (TICC-PCP) 的试点随机对照试验

2025-10-240
OA
Personalised Exercise Rehabilitation FOR people with Multiple long-term conditions (PERFORM): findings from a process evaluation of a randomised feasibility study

个性化运动康复对多种长期疾病患者的影响(PERFORM):一项随机可行性研究的过程评估发现

2025-09-171
OA
Personalised exercise-rehabilitation for people with multiple long-term conditions (PERFORM): a randomised feasibility study

针对患有多种长期疾病人群的个性化运动康复(PERFORM):一项随机可行性研究

2025-09-171
OA
Pharmacy Homeless Outreach Engagement Non-medical Independent Prescribing Rx (PHOENIx) Community Pharmacy-Based Pilot Randomized Controlled Trial

药学无家可归者外展参与非医疗独立处方 Rx (PHOENIx) 社区药房为基础的试点随机对照试验

2025-06-090
OA
An automation framework for clinical codelist development validated with UK data from patients with multiple long-term conditions

一个用于临床码表开发的自动化框架,已使用来自患有多种长期疾病患者的英国数据进行了验证

2025-05-240
OA
Multimorbidity clusters and their associations with health-related quality of life in two UK cohorts
2025-01-080
OAAI
Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening

一项关于肺癌生物标志物以选择低剂量CT筛查人群的随机对照试验中的五年死亡率

2025-01-081
OA
Patient and Public Involvement in Research Evaluating Integrated Care for People Experiencing Homelessness: Findings From the PHOENIx Community Pharmacy Pilot Randomised-Controlled Trial
2024-10-180
OA